<DOC>
	<DOCNO>NCT00247130</DOCNO>
	<brief_summary>The present study compare hemostasis-maintaining effect intravenous omeprazole ranitidine patient upper gastrointestinal hemorrhage undergone endoscopic hemostasis , establish anti-secretory medication prior start oral alimentation effective prevent re-hemorrhage hemostasis .</brief_summary>
	<brief_title>Comparison Intravenous Omeprazole Ranitidine Recurrent Bleeding After Endoscopic Treatment Bleeding Ulcer</brief_title>
	<detailed_description>Gastrointestinal hemorrhage relatively common condition , source bleed commonly upper gastrointestinal tract , especially gastric duodenal ulcer . It often require emergency treatment . First , site bleeding determine . If expose blood vessel find hemorrhagic lesion , case ooze projectile hemorrhage , endoscopic hemostasis perform lesion . After hemostasis achieve , prevention re-bleeding important ; usually , antacid similar medication administer course monitor fasting conditions.Suppression gastric acid secretion necessary raise gastric pH level maintain normal blood coagulation , promote heal hemorrhagic lesion . In Japan , intravenous preparation H2 receptor antagonists proton pump inhibitor commonly used.In foreign country , drug therapy patient upper gastrointestinal hemorrhage emphasize maintenance normal blood coagulation . High dos drug establish constantly maintain pH 7 stomach ( Daneshmend TK , et al. , BMJ 1992 , 304:143-147 ; Labentz J , et al. , Gut 1997 , 40:36-41 ; Hasselgren G , et al. , Scand J Gastroenterol 1997 , 32:328-333 ; Schaffalitzky de Muckadell OB , et al. , Scand J Gastroenterol 1997 , 32:320-327 ; Sung JJY , et al. , Ann Intern Med 2003 , 139:237-243 ) . In clinical study , proton pump inhibitor superior H2 receptor antagonist term clinical efficacy ( Labentz J , et al. , Gut 1997 , 40:36-41 ) . In Japan , emphasis place promote heal lesion since endoscopic hemostasis fairly common practice ; dos establish level similar therapeutic dos peptic ulcer . It say , however , superiority intravenous proton pump inhibitor H2 receptor antagonist establish dos . This possibly attribute fact previous study study population homogenous term severity ; example , patient require endoscopic hemostasis included.Against background , study compare hemostasis-maintaining effect intravenous omeprazole ranitidine patient upper gastrointestinal hemorrhage undergone endoscopic hemostasis , establish anti-secretory medication prior start oral alimentation effective prevent re-hemorrhage hemostasis .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>Patients identify gastric duodenal ulcer Patients hemorrhagic expose vessel ulcer lesion , ooze projectile hemorrhage ( predominantly arterial ) ulcer , endoscopic hemostasis perform . Over 20 year age either sex . The subject proxy consenter provide write informed consent . Serious hepatopathy , nephropathy , heart disease . Complicating malignant tumor . Hemorrhage malignant tumor . The patient , need , treatment drug consider interact test drug . History allergy test drug . History anaphylactic shock . Pregnant , possibly pregnant , lactate . patient unable fully understand explanation study . patient judge investigator otherwise inappropriate inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Omeprazole</keyword>
	<keyword>Ranitidine</keyword>
	<keyword>Endoscopic treatment</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Peptic ulcer</keyword>
</DOC>